Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Serogroup B Meningococcal Disease”

46 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 46 results

Testing effectiveness (Phase 2)Study completedNCT02534935
What this trial is testing

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Who this might be right for
Meningococcal B Disease
Pfizer 396
Testing effectiveness (Phase 2)Study completedNCT00808028
What this trial is testing

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Who this might be right for
Meningitis, Meningococcal
Pfizer 538
Post-approval studies (Phase 4)Study completedNCT02569632
What this trial is testing

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Who this might be right for
Meningococcal Infections
UCSF Benioff Children's Hospital Oakland 18
Early research (Phase 1)Study completedNCT00248833
What this trial is testing

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Who this might be right for
Meningitis, Meningococcal, Serogroup B
U.S. Army Medical Research and Development Command 34
Not applicableStudy completedNCT01452438
What this trial is testing

Safety Surveillance of MenACWY-CRM Vaccine in Children

Who this might be right for
Meningococcal Disease
Novartis Vaccines 393
Large-scale testing (Phase 3)Study completedNCT00661713
What this trial is testing

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Who this might be right for
Meningococcal Disease
Novartis Vaccines 1,631
Large-scale testing (Phase 3)Study completedNCT00291343
What this trial is testing

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 296
Post-approval studies (Phase 4)Looking for participantsNCT06832514
What this trial is testing

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

Who this might be right for
Meningococcal Meningitis, Serogroup BTransgender PersonsSex Differences in Immune Response+1 more
University Ghent 250
Not applicableStudy completedNCT00161941
What this trial is testing

Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216

Who this might be right for
Meningococcal Meninigitis, Serogroup C
Pfizer 321
Post-approval studies (Phase 4)Active Not RecruitingNCT06113198
What this trial is testing

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Who this might be right for
Meningitis, Meningococcal
GlaxoSmithKline 50
Testing effectiveness (Phase 2)Study completedNCT00135564
What this trial is testing

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 500
Testing effectiveness (Phase 2)Ended earlyNCT04645966
What this trial is testing

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Who this might be right for
Meningococcal Vaccine
Pfizer 326
Post-approval studies (Phase 4)Study completedNCT01593514
What this trial is testing

Understanding the Immune Response to Two Different Meningitis Vaccines

Who this might be right for
MeningitisMeningococcal DiseaseSepticaemia
University of Oxford 20
Large-scale testing (Phase 3)Study completedNCT02305446
What this trial is testing

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Who this might be right for
Meningitis, Meningococcal, Serogroup B
Novartis 55
Post-approval studies (Phase 4)Study completedNCT02080559
What this trial is testing

Investigating the Immune Response to 4CMenB in Infants

Who this might be right for
Meningitis
University of Oxford 187
Not applicableStudy completedNCT01452464
What this trial is testing

Safety of MenACWY-CRM Vaccination in Adolescents

Who this might be right for
Meningococcal Disease
Novartis Vaccines 55,397
Testing effectiveness (Phase 2)Study completedNCT00129116
What this trial is testing

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Who this might be right for
Haemophilus Influenzae Type bNeisseria Meningitidis
GlaxoSmithKline 388
Large-scale testing (Phase 3)Study completedNCT00289783
What this trial is testing

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Who this might be right for
Haemophilus Influenzae Type bNeisseria Meningitidis
GlaxoSmithKline 4,441
Testing effectiveness (Phase 2)Study completedNCT00127855
What this trial is testing

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Who this might be right for
Haemophilus Influenzae Type bNeisseria Meningitidis
GlaxoSmithKline 409
Large-scale testing (Phase 3)Study completedNCT01352793
What this trial is testing

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Who this might be right for
Meningitis, Meningococcal
Pfizer 5,715
Next Page